{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:22:23Z","timestamp":1792030943243,"version":"4.4.0"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T00:00:00Z","timestamp":1092009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The aim of this study was to investigate the potential use of mirtazapine in Korean veterans diagnosed with PTSD, by comparing it with sertraline, a drug approved for use in PTSD in the USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Efficacy was evaluated by the clinician administered PTSD scale (CAPS\u20102), the Hamilton rating scale for depression (HAMD\u201017) and the clinical global impression scale (CGI), at baseline and at weeks 1, 2 and 6. A response was defined as a \u2265\u200930\u2009% decrease in CAPS\u20102 total severity, a \u2265\u200950\u2009% decrease in total HAMD\u201017 score, and a CGI\u2010I score &lt;\u20093.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>51 patients on mirtazapine (mean age\/duration of illness: 59.1\/33.5 years) and 49 on sertraline (mean age\/duration of illness: 60.6\/35.6 years) completed the study. The mean daily dosage was 34.1\u2009mg for mirtazapine and 101.5\u2009mg for sertraline. On the CAPS\u20102 total score more patients responded in the mirtazapine group at week 1 (13 vs 2\u2009%) and week 2 (51 vs 31\u2009%). At week 6 this difference was statistically significant (88\u2009% vs 69\u2009%, <jats:italic>p<\/jats:italic>\u2009=\u20090.039) on the CAPS\u20102 total score. The HAMD\u201017 total score and CGI\u2010I score decreased in both groups, with no significant differences between th groups on all time points. The main side effects for the mirtazapine group were: dry mouth (19.6\u2009%), constipation (19.6\u2009%), somnolence (15.7\u2009%) and weight gain (1.96\u2009%); and for the sertraline group: indigestion (14.3\u2009%), palpitation (6.1\u2009%), agitation (2.0\u2009%), epigastric soreness (2.0\u2009%), insomnia (2.0\u2009%) and sexual dysfunction (2.0\u2009%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mirtazapine appeared to be an effective and well\u2010tolerated treatment for PTSD in Korean veterans. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.615","type":"journal-article","created":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T23:04:39Z","timestamp":1092092679000},"page":"489-494","source":"Crossref","is-referenced-by-count":75,"title":["Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial"],"prefix":"10.1002","volume":"19","author":[{"given":"Moon Yong","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ho","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Ju","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Mi","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,9]]},"reference":[{"key":"e_1_2_1_2_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2001.tb00198.x"},{"issue":"1","key":"e_1_2_1_4_1","first-page":"S128","article-title":"Effect of mirtazapine in patients with posttraumatic stress disorder: a pilot study","volume":"5","author":"Bahk WM","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"e_1_2_1_5_1","first-page":"60","article-title":"Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety","volume":"61","author":"Ballenger JC","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000085408.08426.05"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0911"},{"key":"e_1_2_1_8_1","volume-title":"Clinician Administered PTSD Scale (CAPS)","author":"Blake D","year":"1990"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.14.1837"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000054884"},{"key":"e_1_2_1_11_1","unstructured":"ChungMY.1996.The Prevalence and The Analysis of Variables in Veterans with Posttraumatic Stress Disorder. Graduate School of Health Science and Management Yonsei University."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199901000-00003"},{"issue":"5","key":"e_1_2_1_13_1","first-page":"52","article-title":"Pharmacotherapy of posttraumatic stress disorder: treatment options, long\u2010term follow\u2010up, and predictors of outcome","volume":"61","author":"Davidson RT","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.5.485"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01411-7"},{"issue":"4","key":"e_1_2_1_16_1","first-page":"19","article-title":"The pharmacologic profile of mirtazapine","volume":"57","author":"De Boer T","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200108000-00010"},{"key":"e_1_2_1_18_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_1_20_1","first-page":"50","volume-title":"Trauma and the Vietnam Generation","author":"Kulka RA","year":"1990"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0503"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0606"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00013"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.615","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:17:08Z","timestamp":1700151428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,9]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1002\/hup.615"],"URL":"https:\/\/doi.org\/10.1002\/hup.615","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,9]]}}}